Bright Minds Biosciences Inc. (DRUG) News
Follow Bright Minds Biosciences Inc. (DRUG) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
FDA Places Bright Minds Biosciences Seizure Drug Application on Partial Hold
Bright Minds Biosciences said the FDA placed its drug application and planned trial for a seizure treatment on partial clinical hold following a review. The stock fell 36% to $35 in premarket trading Monday.
REGULATION | Nov 02, 2026, 01:19 PM UTC
M
DRUG: trading halted on Nasdaq — news pending (7:25 AM ET)
Nasdaq halted trading in DRUG (news pending) at 7:25 AM ET.
EQUITY | Nov 02, 2026, 12:25 PM UTC
L
Bright Minds Biosciences to present at upcoming conferences
Bright Minds Biosciences, Inc. says it will present at upcoming conferences. The company focuses on developing highly selective 5-HT2 agonists for drug-resistant epilepsy, Prader-Willi Syndrome, depression and other indi
EQUITY | Sep 04, 2026, 08:37 PM UTC
L
DRUG - Bright Minds Biosciences to Present at Upcoming Conferences
DRUG - Bright Minds Biosciences to Present at Upcoming Conferences
EQUITY | Sep 04, 2026, 08:30 PM UTC